Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles - 30/05/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | An aptamer conjugated ligand was synthesized. |
• | APT-CUR/CTX-LPNs exhibited good cell inhibition ability. |
• | APT-CUR/CTX-LPNs offered promise for prostate cancer therapy. |
Abstract |
Prostate cancer (PC) is the most common type of newly diagnosed malignancy in men. Combined chemotherapy has been shown to be an effective strategy for the treatment of PC therapy. Lipid-polymer hybrid nanoparticles (LPNs) are core-shell nanoparticles composed of a polymer core and a lipid shell, which are reported to provide significant advantages for combined PC therapy. This study synthesized an aptamer conjugated ligand and designed an aptamer-functionalized, curcumin (CUR) and cabazitaxel (CTX) co-delivered LPNs (APT-CUR/CTX-LPNs). APT-CUR/CTX-LPNs had a mean size of 121.3 ± 4.2 nm and a positive surface charge (23.5 ± 2.6 mV). Both CUR and CTX were sustained released from LPNs. Aptamer-functionalized APT-CUR/CTX-LPNs exhibited good cell inhibition ability, high tumor accumulation, and remarkable tumor inhibition efficiency at the drug ratio of 2:5 (CUR:CTX). The novel LPNs offers great promise for the double drugs delivery to the prostate cancer cells and tumor xenograft in vivo, showing the potential of synergistic combination therapy for prostate cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Prostate cancer, Lipid-polymer hybrid nanoparticles, Aptamer, Curcumin, Cabazitaxel
Plan
Vol 127
Article 110181- juillet 2020 Retour au numéro
Article précédent
- Tumor suppressor p53 independent apoptosis in HT-29 cells by auransterol from Penicillium aurantiacobrunneum
- Gerardo D. Anaya-Eugenio, Choon Yong Tan, L. Harinantenaina Rakotondraibe, Esperanza Carcache Carcache de Blanco
- miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway
- Jinxia Wang, Chengyi Wang, Qian Li, Chunmei Guo, Weibin Sun, Dongting Zhao, Sixiong Jiang, Lihong Hao, Yuxiang Tian, Shuqing Liu, Ming-Zhong Sun
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?